Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

global access

- PMLiVE

Aqilion initiates phase 1 clinical trial for chronic inflammatory diseases

The Regulus programme is working to develop a next-generation JAK1 inhibitor for eosinophilic oesophagitis

- PMLiVE

JCVI publishes statement on London polio vaccination strategy

A total of 116 cases of the virus has been found in London’s wastewater since February

- PMLiVE

AstraZeneca and Daiichi Sankyo announce results for lung cancer therapy

Initial results for the combination therapy – with Merck’s Keytruda – show an overall response rate of 37% in patients with non-small cell lung cancer

- PMLiVE

My body. My choice. Are we all talking about the same thing?

By now you have all heard. In fact, the world has heard. The US Supreme Court has overturned Roe v Wade. The constitutional right to abortion in the US no...

- PMLiVE

BeiGene announces positive phase 3 trial results for liver cancer treatment

There were more than 900,000 new cases in 2020 of the most common type of primary liver cancer – unresectable hepatocellular carcinoma

- PMLiVE

Sanofi halts recruitment for trials assessing MS treatment

The pause in enrolment follows advice issued by the Independent Data Monitoring Committee

- PMLiVE

Michael J Fox Foundation awards Koneksa second research grant

The grant will be used to evaluate whether digital biomarkers can help to predict the different stages of Parkinson’s disease

- PMLiVE

FDA approves Bot Image’s AI software for the detection and diagnosis of prostate cancer

ProstateID combines artificial intelligence with traditional MRI scanning to significantly improve radiologic interpretation accuracy

- PMLiVE

Merck and Cerevance to research novel targets in Alzheimer’s disease

The total value of the deal is expected to be around $1.1bn

- PMLiVE

Merck and Cerevance to research novel targets in Alzheimer’s disease

The total value of the deal is expected to be around $1.1bn

- PMLiVE

Strategic commitment

Life sciences businesses, such as pharmaceuticals and medical technology, are characterised by a high proportion of educated people in roles that have high discretion. That is, you can’t tell them...

- PMLiVE

AstraZeneca and Daiichi Sankyo get FDA approval for breast cancer drug

Results from a phase 3 trial showed Enhertu reduced the risk of disease progression or death by 50%

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links